Novavax (NASDAQ:NVAX) Price Target Raised to $16.00

Novavax (NASDAQ:NVAX) had its price target boosted by HC Wainwright from $11.00 to $16.00 in a research report sent to investors on Friday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other research firms also recently weighed in on NVAX. Wall Street Zen downgraded Novavax from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. JPMorgan Chase & Co. decreased their target price on shares of Novavax from $7.00 to $6.00 and set an “underweight” rating for the company in a research note on Tuesday, November 18th. B. Riley Financial reaffirmed a “buy” rating and set a $16.00 price target (down from $18.00) on shares of Novavax in a research report on Monday, November 10th. BTIG Research reissued a “buy” rating and issued a $19.00 price objective on shares of Novavax in a research report on Tuesday, January 20th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Novavax in a research note on Monday, December 29th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and four have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $11.88.

Novavax Stock Down 9.4%

Shares of NASDAQ:NVAX opened at $10.14 on Friday. The company has a debt-to-equity ratio of 5.93, a current ratio of 2.13 and a quick ratio of 2.10. The stock has a market cap of $1.65 billion, a price-to-earnings ratio of 4.21 and a beta of 2.54. The company has a 50 day moving average of $8.34 and a 200-day moving average of $8.02. Novavax has a one year low of $5.01 and a one year high of $11.97.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.77. Novavax had a net margin of 39.19% and a negative return on equity of 673.17%. The business had revenue of $136.40 million for the quarter, compared to the consensus estimate of $90.26 million. During the same period last year, the company posted ($0.51) EPS. Novavax’s revenue for the quarter was up 66.6% on a year-over-year basis. On average, sell-side analysts forecast that Novavax will post -1.46 earnings per share for the current year.

Institutional Investors Weigh In On Novavax

Hedge funds and other institutional investors have recently bought and sold shares of the company. Flagship Harbor Advisors LLC acquired a new position in shares of Novavax during the fourth quarter worth $33,000. Quarry LP bought a new position in shares of Novavax during the third quarter worth about $33,000. State of Wyoming acquired a new position in shares of Novavax in the second quarter worth approximately $52,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Novavax by 25.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,896 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 1,617 shares during the period. Finally, Danske Bank A S bought a new stake in Novavax in the third quarter valued at approximately $64,000. Institutional investors own 53.04% of the company’s stock.

Novavax News Summary

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Q4 results beat: Novavax reported a surprise GAAP profit (EPS $0.11) and ~67% year‑over‑year revenue growth, driven by licensing/milestone revenues — the core reason the stock jumped on the news. Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates
• Positive Sentiment: Strong operational highlights and balance sheet: Full‑year 2025 revenue of ~$1.1B, $225M Sanofi milestones earned, and year‑end cash of ~$751M reduce short‑term financing risk and support pipeline investments. Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
• Positive Sentiment: Analyst upgrade: HC Wainwright raised its price target to $16 and kept a Buy rating, signaling bullish conviction from at least one sell‑side shop. Benzinga
• Neutral Sentiment: Investor access: Management will present at upcoming investor conferences (TD Cowen fireside chat, others) — useful for transparency but not a near‑term catalyst by itself. Novavax to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Market activity: Unusual options flow showed heavy call buying around the earnings move, indicating elevated short‑term speculative interest. (This reflects trader positioning, not fundamental change.)
• Neutral Sentiment: Earnings call transcript posted for deeper detail on results and guidance assumptions. Novavax, Inc. (NVAX) Q4 2025 Earnings Call Transcript
• Negative Sentiment: 2026 revenue guidance disappointed relative to consensus: Management guided revenue of $230M–$270M for 2026, well below street estimates (~$402M), creating concern about demand trends and prompting profit‑taking. Novavax Q4 Press Release / Guidance
• Negative Sentiment: Analyst caution remains: Some analysts argue the bull case needs more proof despite the beat — concerns on sustainability of licensing revenue, product demand and execution could cap multiple expansion. Novavax: The Bear Case Is Broken, But The Bull Case Needs More Proof

About Novavax

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.